Editorial Board ::: Current Cancer Drug Targets

ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)


Volume 16, 9 Issues, 2016


Download PDF Flyer




Current Cancer Drug Targets

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 68th of 213 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Ruiwen Zhang
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.707
5 - Year: 3.446

Editorial Board

Editor-in-Chief:

Ruiwen Zhang
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA



Associate Editor(s):

A.A. Adjei
Roswell Park Cancer Institute
Buffalo, NY
USA

N. Neamati
University of Michigan
Ann Arbor, MI
USA

R. Agarwal
University of Colorado Denver
Aurora, CA
USA

T. Sugimura
The Japan Academy
Tokyo
Japan

F. Ali-Osman
Comprehensive Cancer Center
Duke University Medical Center
Durham, NC
USA

P. Workman
Cancer Research UK Centre for Cancer Therapeutics The Institute for Cancer Research
Surrey
England, UK


Regional Editor(s):

Region: Europe
S. Parodi
National Institute for Research on Cancer
University of Genoa
Genoa
Italy
Region: North America
E.T. Liu
The Jackson Laboratory
Maine, ME
USA
B.A. Teicher
National Cancer Institute
Bethesda, MD
USA
Region: Asia
Y.-Q. Wei
Sichuan University
Chengdu Sichuan
The People's Republic of China

Book Review Editor(s):

W. Wang
Texas Tech University Health Sciences Center
Amarillo, TX
USA


Editorial Board Members:

S.A. Abdulkadir
Vanderbilt University Medical Center
Nashville, TN
USA

J.J. Barchi
National Cancer Institute
Frederick, MD
USA

J. Cao
Stony Brook University
Stony Brook, NY
USA

P.J. Casey
Duke-NUS Medical School Singapore
Singapore
Singapore

E. Cobos
Texas Tech University Health Sciences Center
Lubbock, TX
USA

W.A. Denny
The University of Auckland
Auckland
New Zealand

L. Ferguson (Biography
L. Ferguson

Prof Ferguson obtained a D. Phil. (Oxon,) from the University of Oxford. On her return to New Zealand, she developed a linkage with some anticancer drug developer, who were developing the Auckland Cancer Society Research Centre, based the The University of Auckland, New Zealand. Lynnette had become interested in applying her genetics traning to an understanding of adverse genetic effects of novel drugs. She joined the Cancer Research Centre to set up the Centre for Mutagen Testing, which still functions to test anticancer drugs, novel pharmaceutical products and occupational situations as caner hazards in New Zealand. He rstudies on causes of cancer have led to a sugnificant amount of work on the New Zealand diet, and she maintains a dual interest in drugs and nutrients in the treatment and cause of cancer.

)

University of Auckland
Auckland
New Zealand

J. He
Chinese Academy of Medical Sciences
Beijing
China

I. Holen
University of Sheffield
Sheffield
England

J. Inazawa
Tokyo Medical and Dental University
Tokyo
Japan

R.S. Kerbel
Sunnybrook & Women's College Health Sciences Centre
Toronto, ON
Canada

R. Lakshmanaswamy
Texas Tech University Health Sciences Center at El Paso
Texas, TX
USA

J.-Y. Liu
Indiana University-Purdue University at Indianapolis
Indianapolis, IN
USA

P. Marchetti
INSERM U1172-S
France

D. Mukhopadhyay (Biography
D. Mukhopadhyay

Debabrata (Dev) Mukhopadhyay, Ph.D.: Professor of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Jacksonville, Florida, has a joint appointment with the Department of Physiology and Biomedical Engineering. Before moving to Mayo Clinic as Professor 14 years ago, he was research fellow and later independent investigator followed by as an Associate Professor at Harvard Medical School, Boston. He has been carried out angiogenesis and tumor microenvironment related research and also leading translational nanomedicine program including new drug delivery systems. He has been serving as reviewer for several study sections in NIH and agencies. Recently, he has been appointed as the Florida Department of Health Cancer Research Chair. He has published more than 190 peer-reviewed papers in different journals including Nature, Nature Medicine, Caner Cell, Cancer Research, Nano Letters. He has several patents and has been involved to develop different start up companies in the area of therapy and diagnosis of the diseases.

)

Mayo Clinic Cancer Center, Mayo Clinic
Rochester, MN
USA

K.C. Nicolaou
Scripps Research Institute
San Diego, CA
USA

F. Patrone (Biography
F. Patrone

Dr. Franco Patrone MD obtained specialization degrees in General Medicine, Hematology, and Oncology from the University of Genova, Italy.

Currently Dr. Patrone is an adjunct professor of Internal Medicine in the Departtment. of Internal Medicine, University of Genova. He has published more than 170 scientific publications reported on PubMed.

Dr. Patrone has been, director of the first Medical Clinic and of the Department of Internal Medicine, University of Genoa, as well as of the Internal Medicine and Oncology Clinic and of the Department of Hematology and Oncology, San Martino University Hospital, Genoa, Italy.

)

University of Genova
Genova
Italy

W. Priebe
The University of Texas MD Anderson Cancer Center
Houston, TX
USA

B. Sarkadi (Biography
B. Sarkadi

Balázs Sarkadi, MD, Ph.D., spent several years as a post-doc and then as a visiting scientist at major universities in the United States and Canada. He is research professor at Semmelweis University, member of the Hungarian Academy of Sciences, past president of FEBS, member of several international research societies including the Academia Europeae. His research has been focusing on membrane proteins, including the investigation of ABC membrane transporters, which play a major role in the multidrug resistance of cancer, in general pharmacology, and in stem cell function. He has published more than 250 papers in international scientific journals, with a citation number over 13,000.

)

National Medical Center
Budapest
Hungary

R.K. Srivastava
University of Kansas Medical Center
Kansas City, Kansas
USA

G.S.W. Tsao
University of Hong Kong
Pok Fu Lam
Hong Kong

W. Wang
Hunan University of Chinese Medicine
Hunan
China

Y. Yen
City of Hope Comprehensive Cancer Center
Duarte, CA
USA

L. Zhang
University of Pittsburgh
Pittsburgh, PA
USA

S. Agrawal
Idera Pharmaceuticals, Inc
Cambridge, MA
USA

M. Breccia (Biography
M. Breccia

Dr. Massimo Breccia is assistant physician at Sapienza University of Rome, Azienda Policlinico Umberto I. His scientific interests and publications as author or co-author (more than 300 papers in peer reviewed journals) are mainly focused on biological and clinical aspects of acute and chronic myeloid leukemias and myelodysplastic syndromes. He is a peer-reviewer for several journals such as Blood, Haematologica, Leukemia Research, British Journal of Haematology, etc and member of editorial board of 5 journal (Leukemia Research, Leukemia Research and Treatment, Hematology Reviews, etc).

He is a member of SIE, SIES, EHA and participates as study coordinator in several clinical trials for CML, AML and MDS. He is secretary of GIMEMA QoL Working Party.

)

University of Rome “Sapienza”
Rome
Italy

M. Caraglia
Second University of Naples
Naples
Italy

C.E. Cass
University of Alberta
Edmonton, AB
Canada

S. De Flora (Biography
S. De Flora

MD in 1966. Assistant Professor in 1966, Full Professor in 1975, and Professor Emeritus in 2012 at the University of Genoa (Italy). Director of the Institute of Hygiene and Preventive Medicine (1986-1998) and Department of Health Sciences (1999-2005, 2010-2012). Author of 465 full length papers, 310 of which available in PubMed, cited more than 14,000 times. He collaborated with 150 laboratories all over the world. Member of the editorial board of 16 international journals. Principal investigator in a number of research projects, 10 of which awarded by the US NIH/NCI. He received several awards, among which the honor from MSU (2002), the Sobels Award (2005), and dedication of ICMAA (Brazil, 2010).

)

University of Genoa
Genoa
Italy

A. El-Osta
Baker Medical Research Institute
Victoria
Australia

T. W. Grunt (Biography
T. W. Grunt

Dr. Grunt obtained a doctorate (Ph.D.) in Cell Biology from the University of Salzburg, Austria. Dr. Grunt also holds an Master of Science in Experimental Biology from the University of Salzburg.

Currently Dr. Grunt is also an Associate Professor in the Medical University of Vienna, Austria. He has published more than 80 scientific publications and is a named inventor of several U.S patents.

Dr. Grunt received several awards from the International Society of Differentiation (ISD), the Austrian Association of Clinical Oncology and from the Austrian Society of Hematology and Oncology. He is member of the American Association of Cancer Research (AACR), the European Association of Cancer Research (EACR), the International Society of Differentiation (ISD), the International Society of Cancer Metabolism (ISCaM), and the Union for International Cancer Control (UICC).

)

Medical University Vienna (MUV)
Vienna
Austria

T.-C. He
The University of Chicago Medical Center
Chicago, IL
USA

C. Huang (Biography
C. Huang

Chaunshu Huang is a Professor of Department of Environmental Medicine and Biochemistry and Molecular Pharmacology and Urology, and Deputy Director of Nelson Institute of Environmental medicine, New York University School of Medicine. Dr. Huang published more than 280 research papers with total citation over 11,200. Chuanshu’s major research addresses fundamental questions concerning the responses of mammalian cells to environmental carcinogens at the levels of protein kinases, transcription factors and their target genes, as well as protein modification both in vitro and in vivo. His research also includes elucidation of tumor invasion and metastasis, as well as screening and identifying novel anti-cancer drugs and the molecular mechanisms underlying their anti-cancer effect.

)

New York University School of Medicine
NY
USA

H. Kasuya
Nagoya University School of Medicine
Nagoya Aichi
Japan

J. Kuroda (Biography
J. Kuroda

Junya Kuroda, holder of M.D. and Ph.D. degrees, is an associate professor at the Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine in Kyoto, Japan, and has published more than 120 articles.

Junya Kuroda’s research interests focused on the identification of the disease–specific dysregulation of epigenetics, genetics, cytogenetics, and cell signaling, to develop novel therapeutic strategies and biomarkers for cancers, especially hematologic malignancies, such as leukemias, lymphomas, or myeloma, while also covers clinical researches in hematological oncology.

)

Kyoto Prefectural University of Medicine
Japan

M. Landström (Biography
M. Landström

Dr. Landström obtained a doctorate (Ph.D) in Physiology from the University of Umeå, Sweden. Dr Landström holds a Professor position in Pathology at Umeå University, Sweden. She has published 57 papers in the field of prostate cancer tumor biology and transforming growth factor b (TGFb) signal transduction. She has made several original discoveries in the field of TGFb non-canonical signaling leading to tumor progression. She is an inventor of one issued U.S. patent.

)

Ludwig Institute for Cancer Research
Uppsala
Sweden

Y.-Q. Long
Shanghai Institute of Materia Medica
Shanghai
China

D.J. McConkey
MD Anderson Cancer Center
Houston, TX
USA

M. Mutoh
Shonan Institute of Technology
Fujisawa, Kanagawa
Japan

V.C.O. Njar
University of Maryland School of Medicine
Baltimore, MD
USA

Y. Pommier (Biography
Y. Pommier

Yves Pommier is the Chief of the Developmental Therapeutics Branch, NCI. He obtained his M.D. and Ph.D. from the University of Paris, and has studied DNA topoisomerases and the pharmacology of their inhibitors for the past 30 years. Three of his topoisomerase I inhibitors are in clinical trials. Dr. Pommier also discovered the first HIV-1 integrase inhibitors and the mechanism of action of poly(ADPribose) polymerase inhibitors by trapping PARP-DNA complexes. He pioneered the concept of drugs acting as interfacial inhibitors.

)

National Cancer Institute
Bethesda, MD
USA

E. Prosperi (Biography
E. Prosperi

Dr. Prosperi graduated in Biological Sciences at the University of Pavia (Italy) and performed PhD studies in Physiological Sciences at the University of Milano, and in the Histochemistry Dept. of Leiden University” (Nederland). Dr. Prosperi is a Senior Researcher in the Institute of Molecular Genetics of the Italian National Research Council (CNR), lab of Genome Stability and DNA damage response, with more than 100 publications. Formerly, Lecturer in Physiopathology of the Cell Cycle, in the Medical Faculty of Pavia University, Dr. Prosperi is currently a teacher in the PhD program in “Genetics, Molecular and Cellular Biology” (Pavia University).

)

CNR, Istituto di Genetica Molecolare
Pavia
Italy

S. Scala
National Cancer Institute "G. Pascale"
Naples
Italy

S.K. Srivastava
Texas Tech University Health Sciences Center
Amarillo, TX
USA

K. Vuori (Biography
K. Vuori

Kristiina Vuori, M.D., Ph.D., is President of Sanford Burnham Prebys Medical Discovery Institute (SBP), and Professor and Pauline & Stanley Foster Presidential Chair. She earned her M.D., Ph.D. degrees in Finland, received postdoctoral training at SBP and was appointed to faculty in 1996. She served as Director of the Institute’s NCI-designated Cancer Center in 2005-2013, and she has been President of SBP since 2010. Dr. Vuori was selected PEW Scholar in 1997 and elected to the National Academy of Inventors in 2014. She is co-founder of three biotechnology companies, and her research focuses on cancer metastasis.

)

The Burnham Institute
La Jolla, CA
USA

J.N. Weinstein
The University of Texas MD Anderson Cancer Center
Houston, TX
USA

D. Zaharevitz
National Cancer Institute
Rockville, MD
USA

J. Zhou
Nanjing Medical University
Nanjing
China

J.L.-S. Au
Ohio State University
Columbus, OH
USA

T.R. Burke (Biography
T.R. Burke

Terrence Burke received his Ph.D. in Medicinal Chemistry from the University of Washington (Seattle) and has spent most of his professional career within the Intramural Program of the National Institutes of Health (NIH). He is currently a Senior Investigator in the Chemical Biology Laboratory (National Cancer Institute). He has published more than 300 scientific publications and is a co-inventor on 20 issued U.S. patents.

)

National Cancer Institute
Bethesda, MD
USA

M.P. Carty
National University of Ireland
Galway City
Ireland

W. Cho
Queen Elizabeth Hospital
Hong Kong
Hong Kong

Z. Debyser
Laboratory of Molecular Virology and Gene Therapy
KU Leuven, Leuven
Belgium

M. Esteller
Bellvitge Biomedical Research Institute (IDIBELL)
Catalonia
Spain

M. Haber (Biography
M. Haber

Professor Haber graduated with a PhD from the University of New South Wales, Australia, in the field of chemical carcinogenesis, and undertook post-doctoral positions at the Hadassah Hebrew University, Israel and the Albert Einstein College of Medicine, New York. She is Executive Director of Children’s Cancer Institute, and Head of the Institute’s Experimental Therapeutics Program and is internationally recognised for her world-class research into the treatment of neuroblastoma and acute lymphoblastic leukaemia in children. She has received numerous awards, particularly in terms of translating her research findings into the clinic, including the 2014 Cancer Institute NSW Premier’s Award for Outstanding Cancer Researcher of the Year and in 2015 was appointed an inaugural Fellow of the Australian Academy of Health and Medical Sciences. She has a long and continuous record of peer-reviewed grant funding and an excellent track record with more than 170 journal publications.

)

University of New South Wales
Sydney
Australia

R.J. Ho
University of Washingto
Seattle, WA
USA

N.-ho. Huh
Okayama University Graduate School of Medicine
Okayama
Japan

E.T. Keller (Biography
E.T. Keller

Dr. Keller obtained Doctor of Veterinary Medicine (D.V.M.) and Masters of Preventive Veterinary Medicine (M.P.V.M.) degrees from the University of California, Davis and a doctorate (Ph.D.) in Developmental Biology from the University of Wisconsin, Madison. Currently, Dr. Keller is a Professor in the Departments of Urology and Pathology at the University of Michigan. He has published more than 200 scientific publications.

)

University of Michigan
Ann Arbor, MI
USA

J. C. Lacal
Instituto de Investigación Sanitaria IdiPAZ
Madrid
Spain

P.C. Lin
National Cancer Institute, Frederick
MD
USA

S. Mani
Albert Comprehensive Cancer Center
Bronx, NY
USA

David Mu (Biography
David Mu

Dr. Mu obtained his PhD degree in Chemistry from the University of California at Berkeley with Dr. Judith P. Klinman. Dr. Mu’s postdoctoral research on the topic of human nucleotide excision repair mechanism with Dr. Aziz Sancar at the University of North Carolina at Chapel Hill was cited by the 2015 Nobel Prize in Chemistry awarded to Dr. Aziz Sancar. At present, Dr. Mu is a Professor in the Eastern Virginia Medical School. He is currently on the Editorial Board of Scientific Reports (Nature Publishing Group) and Journal of Cytology and Molecular Biology (Avens Publishing).

)

Eastern Virginia Medical School
Norfolk, VA
USA

A. Nencioni
University of Genoa
Genoa
Italy

Y.-P. Pang
Mayo Clinic Cancer Center
Rochester, MN
USA

G. Powis
Sanford-Burnham Medical Research Institute
La Jolla, CA
USA

D.M. Raben (Biography
D.M. Raben

Dr. Daniel Raben received his PhD in Biochemistry from Washington University. Following a postdoctoral fellowship at the University of California-Irvine, he joined the faculty at The Johns Hopkins University School of Medicine. He has been there for over 30 years and is a Professor of Biological Chemistry, Physiology, and Oncology. He has a national and international reputation for his work the interfacial enzymology of lipid metabolizing enzymes and the role of these enzymes in the nervous system.

)

John Hopkins School of Medicine
Baltimore, MD
USA

M.S. Sheikh
SUNY Upstate Medical University
Syracuse, NY
USA

K.S. Srivenugopal (Biography
K.S. Srivenugopal

Dr. Kalkunte Srivenugopal obtained his Ph.D. in Biochemistry From the Indian Institute of Science. He has been in the United States since 1981 and is currently a tenured Professor of Biomedical Sciences at the Texas Tech University School of Pharmacy in Amarillo, Texas, USA. Dr. Srivenugopal’s research interests include brain tumor chemotherapy, DNA repair, drug discovery, p53 biology and redox signaling. He has received funding from the National Institutes of Health, Cancer Prevention Research Institute of Texas and many private foundations. He has published more than 85 peer-reviewed articles.

)

Texas Tech University Health Sciences Center
Amarillo, Texas
USA

H. Wang
Chinese Academy of Sciences
Shanghai
China

T. Wu
Huazhong University of Science and Technology
Wuhan
China

Z.-F. Zhang
University of California
South Los Angeles, CA
USA

P.-K. Zhou
Beijing Institute of Radiation Medicine
Beijing
China


Advertisement

Related Journals




Related eBooks


Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science